Erythropoiesis Stimulating Agents Demonstrate Safety and Show Promise as Neuroprotective Agents in Neonates
- PMID: 25917767
- PMCID: PMC4795451
- DOI: 10.1016/j.jpeds.2015.03.054
Erythropoiesis Stimulating Agents Demonstrate Safety and Show Promise as Neuroprotective Agents in Neonates
Conflict of interest statement
The other authors declare no conflicts of interest.
Comment on
-
Safety of Early High-Dose Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants.J Pediatr. 2015 Jul;167(1):52-7.e1-3. doi: 10.1016/j.jpeds.2015.02.052. Epub 2015 Apr 8. J Pediatr. 2015. PMID: 25863661 Clinical Trial.
References
-
- Rhondeau SM, Christensen RD, Ross MP, Rothstein G, Simmons MA. Responsiveness to recombinant human erythropoietin of marrow erythroid progenitors from infants with the “anemia of prematurity. J Pediatr. 1988;112:935–40. - PubMed
-
- Fauchere JC, Dame C, Vonthein R, Koller B, Arri S, Wolf M, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics. 2008;122:375–82. - PubMed
-
- Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics. 2008;122:383–91. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical